A.C.A. Müller ADAG Pharma AG
Pharmaceutical Companies · Konstanz
A.C.A. Müller ADAG Pharma AG is a pharmaceutical company based in Konstanz, Baden-Württemberg, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
A.C.A. Müller ADAG Pharma AG Address & Contact
A.C.A. Müller ADAG Pharma AG Overview
A.C.A. Müller ADAG Pharma AG is a well-established company in the field of pharmaceutical supply for many years. Founded in Konstanz, Baden-Württemberg, the company specializes in the distribution of parallel imports and specialty medications. These products are sourced from various EU countries, allowing them to be offered at reduced prices in the German market. This is particularly important as competition in the German pharmaceutical market is intense, and innovative pricing strategies play a central role.
Services and Products
ADAG Pharma consistently upholds the highest quality standards. The outstanding services include, among others:
- Parallel Imports: Original medicinal products from renowned manufacturers are procured, which are available at lower rates due to price differences in other EU countries.
- Specialty Medications: In addition to common products, the range also includes specialized medications for niche markets that are often not widely available in Germany.
- Quality Control: All imported medications are repackaged and quality tested according to the strict regulations of the German Medicines Act to ensure they meet high German standards.
- Sales and Logistics: The company works closely with established logistics partners to guarantee GDP-compliant distribution (Good Distribution Practice). Emphasis is placed on efficiency and safety at every stage of delivery.
Additionally, A.C.A. Müller ADAG Pharma AG holds all necessary BfArM import licenses (Federal Institute for Drugs and Medical Devices), indicating the regulatory compliance of the company and fostering trust among pharmaceutical wholesalers and pharmacies.
Regulatory Classification
In the German healthcare system, pharmaceutical imports are carefully regulated to protect public health. The import of medications is subject to strict rules to ensure that only products of the highest quality enter the market. A.C.A. Müller ADAG Pharma AG meets all requirements and has established itself as a reliable partner in the field of parallel imports. Compliance with European and national regulations enables the company to assert itself in the omnipresent competition and to instill trust in its customers.
Regional Significance
The geographical location of Konstanz at the tri-border region of Germany, Switzerland, and Austria significantly contributes to the importance of A.C.A. Müller ADAG Pharma AG. Konstanz is not only a beautiful city on Lake Constance but also a hub for international pharmaceutical companies. The proximity to Switzerland, a leading location in pharmaceutical research and development, allows ADAG Pharma to benefit from innovative developments and products. In a time when pharmaceutical companies worldwide are increasingly working interdisciplinarily, this location is of strategic advantage.
Special Features of A.C.A. Müller ADAG Pharma AG
An outstanding feature of A.C.A. Müller ADAG Pharma AG is its commitment to innovation and patient care. By importing specialty medications that are often difficult to obtain in Germany, the company not only supports local pharmacies but also improves access for patients with special medical needs. Furthermore, ADAG Pharma maintains close relationships with manufacturers and suppliers within the EU, enabling agile responses to market needs and price changes.
More Pharmaceutical Companies: Overview of Pharmaceutical Companies | Pharmaceutical Companies in Baden-Württemberg | Pharmaceutical Wholesalers
```Frequently asked questions about A.C.A. Müller ADAG Pharma AG
What does A.C.A. Müller ADAG Pharma AG do?
A.C.A. Müller ADAG Pharma AG is a pharmaceutical company based in Konstanz that develops, manufactures or distributes pharmaceutical products. The company is active in the German healthcare market.
Where is A.C.A. Müller ADAG Pharma AG located?
A.C.A. Müller ADAG Pharma AG is headquartered in Konstanz, Germany. More information can be found on the company's website.
What products does A.C.A. Müller ADAG Pharma AG distribute?
A.C.A. Müller ADAG Pharma AG is active in the pharmaceutical sector. Detailed information on the products offered and therapeutic areas can be found on the company's website or via the contact details provided.
More Pharmaceutical Companies in Konstanz
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.